Desmoid Tumor Drug Pipeline — PatSnap Eureka
Desmoid Tumor Drug Pipeline: Gamma Secretase Inhibitors, Sorafenib & Notch Pathway Approaches
No systemic therapy has received regulatory approval for desmoid tumors — yet multiple targeted agents including GSIs, multikinase inhibitors, and direct Wnt/β-catenin inhibitors are advancing through preclinical and early clinical evaluation. Explore the full pipeline with PatSnap Eureka.
Wnt/β-Catenin: The Central Oncogenic Driver of Desmoid Tumors
Desmoid tumors (DT) — also termed desmoid-type fibromatosis or aggressive fibromatosis — are rare, locally invasive mesenchymal neoplasms of intermediate malignancy. The molecular driver identified most frequently across the literature is the Wnt/β-catenin signaling pathway, anchored by somatic mutations in CTNNB1 (encoding β-catenin) in sporadic DT and germline mutations in APC in familial adenomatous polyposis (FAP)-associated DT. These two mutation types are described as mutually exclusive.
Constitutive nuclear β-catenin activity is the central oncogenic event. Cross-talk between the Notch and Wnt pathways — and dysregulation of the Notch pathway as a downstream consequence of aberrant Wnt signaling — provides the mechanistic rationale for targeting gamma secretase, the enzyme that cleaves the Notch intracellular domain (NICD) to enable nuclear translocation and gene transcription activation (Federman et al., UCLA, 2022).
Secondary pathway targets identified in the dataset include TGF-β signaling — characterized at Yonsei University through elevated alpha-SMA expression and TGF-β pathway activation in DT tissues — as well as PDGFR, VEGFR (via angiogenesis-targeted agents), and COX-2/prostaglandin pathways. The PatSnap life sciences platform enables researchers to map these pathway interactions across the full patent and literature corpus.
Multi-omics studies in pediatric DT (98 extra-abdominal cases, Jiangsu Cancer Hospital) further identified novel mutations and prognostic markers through whole exome sequencing, RNA sequencing, and untargeted metabolomics, signaling an expanding genomic understanding of the disease beyond CTNNB1/APC. As the Erasmus MC literature review underscores, the broader landscape of DT-driving signaling remains incompletely characterized, and few drugs directly targeting this pathway have entered clinical practice.
Six Drug Classes Advancing in the Desmoid Tumor Pipeline
From gamma secretase inhibitors to drug repositioning, the desmoid tumor landscape spans mechanistically distinct approaches — all targeting a disease with no approved systemic therapy.
Gamma Secretase Inhibitors (GSIs) — Notch Pathway
GSIs block gamma secretase-mediated cleavage of the Notch receptor, preventing NICD nuclear translocation. Two named agents — AL101 (Ayala Pharmaceuticals) and PF-03084014/nirogacestat (SpringWorks Therapeutics) — are under investigation for DT. AL101 has case report-level clinical data in 2 adult DT patients (2021). The mechanistic rationale is the Notch/Wnt cross-talk downstream of aberrant Wnt signaling in CTNNB1/APC-mutant tumors.
Case report (AL101) · Preclinical + clinical (nirogacestat)Multikinase Inhibitors — Sorafenib, Pazopanib, Anlotinib
Pazopanib (VEGFR1/2/3, PDGFRα/β inhibitor) has the most extensive DT documentation: two case reports from The Royal Marsden Hospital showing radiological responses lasting over 12 months, and a complete response case from Ege University. Sorafenib was used in a pediatric DT case (CTNNB1 T41A) in combination with celecoxib. Anlotinib + celecoxib is documented for abdominal DT (Henan Cancer Hospital, 2022).
Case series (pazopanib) · Case reports (sorafenib, anlotinib)Wnt/β-Catenin Direct Inhibitors — Tegavivint (BC2059)
Tegavivint (BC2059) is a selective inhibitor of nuclear β-catenin acting through TBL-1 binding. Ohio State University demonstrated preclinical activity in DT cell lines and ex vivo explant tissue models (2022). Critically, this compound is described as "the only one being evaluated in a clinical study, specifically for treatment of desmoid tumor patients" — positioning it as a potential first-in-class agent in a regulatory white space.
Preclinical data published · Clinical study ongoingAuranofin — FDA-Approved Repositioning Candidate
Nagoya University investigators identified auranofin (an FDA-approved anti-rheumatic gold compound) as an effective inhibitor of DT cell proliferation harboring CTNNB1 S45F mutations. Effects were confirmed in Apc1638N mice in vivo. The mechanism was found to be β-catenin-independent at the protein expression level, suggesting a novel mechanism distinct from direct Wnt inhibition — and an established safety profile that could accelerate clinical evaluation timelines.
Preclinical (in vitro + Apc mouse model)Imatinib, Anti-Estrogens, NSAIDs & COX-2 Inhibitors
The Mayo Clinic management algorithm includes NSAIDs, anti-estrogens, and imatinib for symptomatic or progressive DT. Meloxicam (selective COX-2 inhibitor) produced PR in 10 of 20 evaluable patients by RECIST criteria (Nagoya University institutional series). Imatinib has been evaluated in the Phase II Desminib trial. Toremifene (anti-estrogen) modulates MMP/TIMP expression in desmoid fibroblasts (University of Perugia).
Phase II (imatinib) · Institutional clinical use (meloxicam)Anti-Angiogenic Monoclonal Antibodies — Bevacizumab
A case report from Hannover Medical School documents single-agent bevacizumab producing both symptomatic and radiological response with excellent tolerability in a patient with progressive DT after chemotherapy failure — described as the first reported case of single-agent bevacizumab in DT. The mechanism in DT is presumed to be anti-angiogenic rather than direct tumor cell targeting, paralleling the rationale for pazopanib.
Single-patient proof-of-principle (2016)Clinical Evidence Levels & Combination Strategy Signals
Data visualisations derived from patent and literature analysis via PatSnap Eureka. All values reflect retrieved evidence in the dataset.
Clinical Evidence Level by Desmoid Tumor Agent
Imatinib (Phase II Desminib trial) represents the highest clinical evidence level; AL101, nirogacestat, and Tegavivint are at case report or early clinical stage.
Desmoid Tumor Pipeline by Therapeutic Class
GSIs are the most prominently featured DT-specific targeted approach in the retrieved dataset, followed by multikinase inhibitors and direct Wnt/β-catenin inhibitors.
Key Agents: Evidence Stage, Institution & Mutation Context
Retrieved results provide several clinical or near-clinical signals specifically for desmoid tumors. No regulatory submissions or approved therapies are documented in the dataset.
| Agent | Class | Evidence Stage | Key Institution | Mutation Context | Year |
|---|---|---|---|---|---|
| AL101 | Gamma Secretase Inhibitor | Case Report | Ayala Pharmaceuticals | CTNNB1/APC mutations (Notch/Wnt rationale) | 2021 |
| Nirogacestat (PF-03084014) | Gamma Secretase Inhibitor | Preclinical + Clinical | MD Anderson Cancer Center / UCLA | Notch pathway expression confirmed in DT tissues | 2015–2022 |
| Tegavivint (BC2059) | Wnt/β-Catenin Inhibitor (TBL-1) | Clinical Ongoing | Ohio State University | CTNNB1-mutant DT cell lines and ex vivo models | 2022 |
| Pazopanib | Multikinase Inhibitor (VEGFR/PDGFR) | Case Series | Royal Marsden Hospital / Ege University | Progressive DT/AF (response >12 months; 1 CR reported) | 2013–2016 |
| Imatinib | Tyrosine Kinase Inhibitor | Phase II (Desminib) | Leon Berard Cancer Center / Medical Univ. Graz | Unresectable DT; also concurrent with radiation (Stanford) | 2010–2017 |
| Meloxicam | COX-2 Inhibitor / NSAID | Institutional Series | Nagoya University | PR in 10/20 evaluable patients by RECIST | 2012 |
Search the Desmoid Tumor Patent & Literature Corpus
PatSnap Eureka combines patent intelligence with literature analysis to map the full competitive landscape for rare oncology indications.
Emerging Combination Rationales in the Desmoid Tumor Pipeline
Retrieved results signal several combination strategies at varying stages of evidence, with COX-2 inhibition appearing as a recurrent backbone across multiple DT regimens.
Sorafenib + Celecoxib (COX-2)
Demonstrated in a pediatric DT case with CTNNB1 T41A somatic mutation (Hospital Infantil Gregorio Marañón, Madrid, 2021). The concurrent use suggests an emerging rationale for dual-targeted plus anti-inflammatory approaches in mutation-stratified patients. Secondary effects associated with sorafenib required treatment modification.
Anlotinib + Celecoxib (COX-2)
Documented as a clinical case for abdominal DT (Affiliated Cancer Hospital of Zhengzhou University, 2022). This signal parallels the sorafenib/celecoxib combination, suggesting COX-2 inhibition may be a favored backbone for combination approaches in DT — supported by the low-toxicity profile of COX-2 inhibitors.
Imatinib + Radiation (Stanford Series)
A Stanford retrospective series of 4 patients with unresectable symptomatic DT treated with concurrent imatinib and radiation — all showing response. This is the only multi-patient combination clinical report in the dataset for DT, representing a local plus systemic combination approach (Stanford University, 2017).
Multi-Omics-Guided Target Discovery
Jiangsu Cancer Hospital (WES, RNA-seq, metabolomics on 98 pediatric DT cases) and Yonsei University (TGF-β pathway profiling, patient-derived models) are expanding the therapeutic target space beyond CTNNB1/APC. Patient-derived models enable pre-clinical validation of novel targets in a DT-specific biological context.
Key Institutions Driving Desmoid Tumor Research
Activity in the retrieved dataset is entirely literature-driven (academic papers); no patent filings specifically addressing desmoid tumor GSIs or Notch pathway targeting were retrieved. This signals a potential IP gap — drug developers entering this space should consider composition-of-matter and method-of-treatment filings for GSI use in CTNNB1/APC-mutant desmoid tumor. The mechanistic rationale is now well-documented in the academic literature but commercial IP coverage is not evident in this dataset. The PatSnap analytics platform can be used to conduct freedom-to-operate and white space analyses across this domain.
MD Anderson Cancer Center contributed the foundational preclinical mechanistic study on PF-03084014 in DT cell lines (2015), representing an early and detailed characterization of Notch pathway targeting in DT. UCLA published the 2022 comprehensive review of DT molecular pathogenesis and GSI rationale, naming both nirogacestat and AL101 in the clinical context.
Ohio State University generated the preclinical efficacy data for Tegavivint/BC2059 in DT cell lines and ex vivo models, with the dataset noting ongoing clinical evaluation. Nagoya University contributed both the institutional COX-2 inhibitor series (meloxicam, PR in 10/20 patients) and the drug repositioning auranofin study.
For rare disease drug developers, understanding institutional publication patterns is as important as patent landscape analysis. PatSnap customers use Eureka to track academic-to-commercial translation signals across rare oncology indications — including identifying when preclinical data from a specific institution is likely to translate into IP filings or clinical trial registrations. WHO and FDA rare disease designations further shape the regulatory and commercial landscape for desmoid tumor drug development.
What the Desmoid Tumor Pipeline Signals for Drug Developers
Key strategic takeaways derived from patent and literature analysis via PatSnap Eureka. All claims are traceable to retrieved data.
Potential IP Gap in GSI / Notch Pathway Applications for DT
No patent filings specifically addressing desmoid tumor GSIs or Notch pathway targeting were retrieved in this dataset. The mechanistic rationale is now well-documented in academic literature (MD Anderson 2015, UCLA 2022), but commercial IP coverage is not evident. Drug developers should consider composition-of-matter and method-of-treatment filings for GSI use in CTNNB1/APC-mutant desmoid tumor. Use PatSnap analytics for white space analysis.
White space opportunity identifiedTegavivint: Potential First-in-Class in Regulatory White Space
No approved systemic therapy for DT is documented in the retrieved results, confirming the unmet need. Tegavivint/BC2059 is described as the only Wnt/β-catenin inhibitor in a DT-specific clinical study — positioning it as a potential first-in-class agent. This has significant IP strategy implications for the β-catenin/TBL-1 interaction as a novel mechanism of action. PatSnap life sciences solutions support regulatory pathway analysis.
First-in-class positioning · Regulatory white spaceCOX-2 Inhibition as a Recurrent Combination Backbone
COX-2 inhibition (celecoxib, meloxicam) appears as a recurrent combination backbone across multiple retrieved DT regimens — paired with sorafenib, anlotinib, and as monotherapy. The low-toxicity profile of COX-2 inhibitors makes them attractive combination partners for newer targeted agents. Meloxicam achieved PR in 10/20 evaluable patients by RECIST (Nagoya University). Prospective evaluation in combination trial designs is warranted.
Recurrent across sorafenib, anlotinib, monotherapyCTNNB1 Mutation Status Alone May Not Predict GSI Response
Companies developing GSIs for DT should monitor Notch/Wnt biomarker correlates for patient stratification — CTNNB1 mutation status alone may not fully predict GSI response. The distinction between CTNNB1 (sporadic DT) and APC (FAP-associated DT) mutations has implications for patient stratification in clinical trials. Multi-omics profiling (WES, RNA-seq, metabolomics) is expanding the target landscape beyond these canonical mutations.
Notch/Wnt biomarker correlates neededDesmoid Tumor Drug Pipeline — Key Questions Answered
The dominant driver is the Wnt/β-catenin signaling pathway. Somatic mutations in CTNNB1 (encoding β-catenin) are found in sporadic desmoid tumors, while germline mutations in APC are associated with FAP-related desmoid tumors. These two mutation types are mutually exclusive. Constitutive nuclear β-catenin activity is the central oncogenic event.
Gamma secretase inhibitors (GSIs) block gamma secretase-mediated cleavage of the Notch receptor, thereby preventing Notch intracellular domain (NICD) translocation to the nucleus and Notch-driven gene transcription. The rationale is based on cross-talk between the Notch and Wnt pathways — dysregulation of the Notch pathway occurs as a downstream consequence of aberrant Wnt signaling in desmoid tumors.
Two GSIs are explicitly named in the dataset: AL101 (Ayala Pharmaceuticals) and PF-03084014 (now developed as nirogacestat by SpringWorks Therapeutics). AL101 has case report-level clinical data in 2 adult desmoid tumor patients. PF-03084014 has preclinical mechanistic data from MD Anderson Cancer Center and is described by the UCLA 2022 review as under clinical investigation.
Sorafenib appears in the dataset in the context of pediatric desmoid tumor: a 6-year-old patient with a recurrent mediastinal desmoid tumor harboring a CTNNB1 T41A somatic mutation was administered celecoxib plus sorafenib as targeted combination therapy. Secondary effects associated with sorafenib required treatment modification, but the case demonstrates clinical use of sorafenib in desmoid tumor with a confirmed Wnt pathway mutation.
Tegavivint (BC2059) is a selective inhibitor of nuclear β-catenin acting through TBL-1 binding. It is the only direct β-catenin inhibitor in the retrieved dataset that is explicitly stated to be in clinical evaluation specifically for desmoid tumor patients. Preclinical data from The Ohio State University demonstrated activity in desmoid tumor cell lines and ex vivo explant tissue models.
No approved systemic therapy for desmoid tumors is documented in the retrieved results, confirming the unmet need and regulatory opportunity. Tegavivint/BC2059 is described as the only Wnt/β-catenin inhibitor in a desmoid tumor-specific clinical study, positioning it as a potential first-in-class agent in a regulatory white space.
Still have questions about the desmoid tumor pipeline? Let PatSnap Eureka search patents and literature for you.
Ask Eureka About Desmoid TumorsAccelerate Your Desmoid Tumor Drug Discovery Research
Join 18,000+ innovators already using PatSnap Eureka to map rare oncology pipelines, identify IP white spaces, and track clinical translation signals — all in one AI-native platform.
References
- Activity of the Gamma Secretase Inhibitor AL101 in Desmoid Tumors: A Case Report of 2 Adult Cases — Clinical Development, Ayala Pharmaceuticals, 2021
- Molecular pathogenesis of desmoid tumor and the role of γ-secretase inhibition — Departments of Pediatrics and Orthopedics, UCLA Jonsson Comprehensive Cancer Center, 2022
- Targeting the Notch pathway: A potential therapeutic approach for desmoid tumors — Department of Surgical Oncology, MD Anderson Cancer Center, 2015
- Preclinical efficacy of the Wnt/β-catenin pathway inhibitor BC2059 for the treatment of desmoid tumors — Department of Surgery, Ohio State University, 2022
- Target therapy with celecoxib in pediatric recurrent desmoid tumors: A case report — Department of Pediatrics, Hospital Infantil Gregorio Marañón, Madrid, 2021
- Pazopanib is an active treatment in desmoid tumour/aggressive fibromatosis — The Royal Marsden Hospital, 2013
- Pazopanib: a novel treatment option for aggressive fibromatosis — Ege University, 2016
- Combination of Anlotinib and Celecoxib for the Treatment of Abdominal Desmoid Tumor — Affiliated Cancer Hospital of Zhengzhou University, 2022
- Efficacy of auranofin as an inhibitor of desmoid progression — Nagoya University Graduate School of Medicine, 2022
- Transition of Treatment for Patients with Extra-Abdominal Desmoid Tumors: Nagoya University Modality — Nagoya University, 2012
- Therapeutic Implications of TGF-β Pathway in Desmoid Tumor — Yonsei University College of Medicine, 2022
- Clinical Prognostic Factors and Integrated Multi-Omics Studies Identify Potential Novel Therapeutic Targets for Pediatric Desmoid Tumor — Jiangsu Cancer Hospital / Nanjing Medical University, 2022
- Activated Signaling Pathways and Targeted Therapies in Desmoid-Type Fibromatosis — Erasmus MC, 2022
- Current Perspectives on Desmoid Tumors: The Mayo Clinic Approach — Mayo Clinic, 2011
- Proof of principle for bevacizumab activity in desmoid-type fibromatosis — Hannover Medical School, 2016
- Concurrent Imatinib and Radiation Therapy for Unresectable and Symptomatic Desmoid Tumors — Stanford University, 2017
- Prediction of desmoid tumor progression using miRNA expression profiling — Leon Berard Cancer Center, 2015
- Sorafenib inhibits tumor growth and vascularization of rhabdomyosarcoma cells by blocking IGF-1R-mediated signaling — Karolinska Institutet, 2008
- Human desmoid fibroblasts: matrix metalloproteinases, their inhibitors and modulation by Toremifene — University of Perugia, 2005
- National Center for Biotechnology Information (NCBI) — PubMed literature database
- World Health Organization (WHO) — Rare disease classification and global health data
- U.S. Food and Drug Administration (FDA) — Rare disease and orphan drug designations
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report represents a snapshot of innovation signals within the retrieved dataset only and should not be interpreted as a comprehensive view of the full field, clinical pipeline, or regulatory landscape.
PatSnap Eureka searches patents and research to answer instantly.